Fredun Pharmaceuticals Announces Strategic Launch of Premium Hormone Range Products
Published on: May 16, 2026, 1:20 a.m. | Source: scanx.trade
Fredun Pharmaceuticals Limited announced the strategic launch of its Hormone Range Products on 15th May, 2026, targeting longevity, hormone health, recovery science, and human performance therapeutics. The brand, operating under the name ADARO, is built on a doctor-led, evidence-backed model integrated with a digital-first patient engagement ecosystem. The initial portfolio includes formulations based on testosterone and its salts, nandrolone, and growth hormone-oriented solutions. In FY25, Fredun Pharmaceuticals reported total revenues of ₹ 456 Cr, an EBITDA of ₹ 55 Cr, and a PAT of ₹ 21 Cr.
